Modalis Therapeutics Receives FDA Rare Paediatric Disease Designation for MDL-101 in Treatment of Congenital Muscular Dystrophy (CMD)
Monday, September 30, 2024
Modalis Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to MDL-101.
MDL-101 is an experimental epigenetic therapy that targets the LAMA1 gene, which is highly similar to LAMA2. It employs a guide nucleotide to upregulate LAMA1 expression, delivered via an AAV vector specific to muscle tissue.
LAMA2-CMD is a severe form of congenital muscular dystrophy caused by the absence of the LAMA2 protein, which consists of over 3,000 amino acids.
By compensating for the loss of function caused by LAMA2 mutations, MDL-101 has the potential to provide a long-lasting, one-time treatment for patients with LAMA2-CMD.
This experimental therapy is being developed for congenital muscular dystrophy type 1A (LAMA2-CMD).
The FDA's RPD designation is granted to treatments for serious, life-threatening conditions that primarily affect children under 18 and fewer than 200,000 people in the U.S. Upon marketing approval, this designation makes Modalis eligible for a priority review voucher, allowing expedited review of another product.
The Orphan Drug application for MDL-101 is also under separate review.
Due to its size, conventional gene therapy approaches, such as loading onto an AAV vector, have been challenging, and no current treatments target the root cause of the disease.
Modalis' CRISPR-GNDM® technology enables precise modulation of gene expression without introducing double-strand DNA breaks. MDL-101 is designed to be a first-in-class treatment, compensating for the LAMA2 deficiency by inducing the expression of the sister gene LAMA1 in muscle tissue.
This innovative approach aims to offer a breakthrough therapy for patients with LAMA2-CMD.
Source: modalistx.com
